Boston Scientific sells fluid management, venous access businesses

Performed with Boston Scientific’s NIR stent, now owned by Avista.
Source: Medscape
 
  
Boston Scientific has agreed to sell its fluid management and venous access businesses to a private equity firm for $425 million in cash.

The sale of the two units was part of Boston Scientific’s plan presented in August to divest certain non-strategic assets. The combined units are expected to operate as an independent company under a new name once the deal is complete, according to the company.

Last month, the company began the process to sell its cardiac and vascular surgery businesses to Getinge Group for $750 million.

The fluid management unit makes products to manage and measure fluids during angiography and angioplasties. The venous access division produces devices that allow doctors to deliver drugs and food intravenously.

The Natick, Mass.-based Boston Scientific said that the sale is expected to close in the first quarter of 2008.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.